The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication ...
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults ...
FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...
Arizona couple Michael and Julie Carroll have lost a combined 177 lbs. on a GLP-1 weight loss drug. 'It gave me my ...